Restructuring Charges

12 Months Ended

Dec. 31, 2017

Restructuring And Related Activities [Abstract]

Restructuring Charges

13.     Restructuring Charges

          In September 2017, the Company announced a corporate reprioritization which aimed to re-focus its resources on the core businesses of Crinone progesterone gel and JPS and reduce expenditures on research and development activities associated with the Company’s IVR program with the goal of potentially identifying a partner for one or more of its IVR product candidates. As a result, during the fiscal year ended December 31, 2017, the Company incurred approximately $0.8 million in restructuring charges. The Company accounted for these actions in accordance with ASC 420, Exit or Disposal Cost Obligations.

The following table summarizes the components of the Company’s restructuring activity recorded in the accompanying balance sheet (in thousands):

	Amounts accrued at December 31, 2016		Expense incurred during the year ended December 31, 2017		Amounts paid during the year ended December 31, 2017			Amounts accrued at December 31, 2017
Employee severance, benefits and related costs	$	—	$	412	$	(340	)	$	72
Obligations under manufacturing and development contracts		—		296		(13	)		283
	$	—	$	708	$	(353	)	$	355

In addition, approximately $17,000 in stock-based compensation expense associated with the modification of the exercise period on options held by an executive, approximately $14,000 related to fixed asset impairments resulting from the discontinuation of use on assets associated with programs terminated and approximately $37,500 in prepaid amortization associated with manufacturing contracts were recorded to Restructuring charges. In total, for the year ended December 31, 2017, the Company incurred $0.8 million in restructuring charges.

No significant additional charges are anticipated relating to this restructuring plan. The Company expects to pay approximately $0.2 million and $0.1 million in 2018 and beyond, respectively.